Department of Family and Community Medicine, Saint Louis University School of Medicine, St. Louis, MO 63104, United States; Harry S. Truman Veterans Administration Medical Center, Columbia, MO, United States.
National Center for PTSD and Department of Psychiatry, University of California San Diego, United States.
Drug Alcohol Depend. 2021 Jan 1;218:108365. doi: 10.1016/j.drugalcdep.2020.108365. Epub 2020 Oct 18.
Clinical trials reveal posttraumatic stress disorder (PTSD) improvement leads to decreased substance use among patients with comorbid substance use disorder (SUD). Using administrative medical record data, we determined whether clinically meaningful PTSD Checklist (PCL) (≥20 points) score decreases were positively associated with SUD treatment utilization.
We used a retrospective cohort of Veterans Health Affairs (VHA) medical record data (2008-2015). PTSD Checklist (PCL) scores were used to categorize patients into those with a clinically meaningful PTSD improvement (≥20 point decrease) or not (<20 point decrease or increase). PTSD and SUD were measured by ICD-9 codes. Propensity score weighting controlled for confounding in logistic and negative binomial models that estimated the association between clinically meaningful PTSD improvement and use of SUD treatment and number of SUD clinic visits.
The 699 eligible patients were, on average, 40.4 (±13.2) years old, 66.2% white and 33.1% were married. After controlling for confounding, there was a 56% increased odds of any SUD treatment utilization among those with a PCL decrease ≥20 vs < 20 (OR = 1.56; 95%CI = 1.04-2.33) but there was no association with number of SUD treatment visits.
Clinically meaningful reductions in PTSD symptoms were associated with any SUD treatment utilization but not amount of utilization. Improvement in PTSD symptoms, independent of the treatment modality, may enable SUD treatment seeking.
临床试验显示,创伤后应激障碍(PTSD)的改善会降低合并物质使用障碍(SUD)的患者的物质使用。利用行政医疗记录数据,我们确定 PTSD 检查表(PCL)(≥20 分)评分的临床显著下降是否与 SUD 治疗利用呈正相关。
我们使用了退伍军人事务部(VA)医疗记录数据(2008-2015 年)的回顾性队列。使用 PTSD 检查表(PCL)评分将患者分为 PTSD 改善具有临床意义(≥20 分下降)或不具有临床意义(<20 分下降或增加)的患者。 PTSD 和 SUD 通过 ICD-9 编码进行测量。倾向评分加权控制了逻辑和负二项式模型中的混杂因素,这些模型估计了 PTSD 改善具有临床意义与 SUD 治疗和 SUD 诊所就诊次数之间的关联。
699 名符合条件的患者平均年龄为 40.4(±13.2)岁,66.2%为白人,33.1%已婚。在控制混杂因素后,PCL 下降≥20 分与<20 分相比,任何 SUD 治疗的利用几率增加了 56%(OR = 1.56;95%CI = 1.04-2.33),但与 SUD 治疗就诊次数无关。
PTSD 症状的临床显著减少与任何 SUD 治疗的利用相关,但与利用量无关。 PTSD 症状的改善,独立于治疗方式,可能会促使 SUD 治疗的寻求。